Mark Dunbar, OD
Optometrist · Miami, FLNPI 1639135817
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 21.5%. Reporting peaked in 2019 at $70,250 and has fallen 50.0% since, to $35,098 in 2025. Among optometrist clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 367 payments — averaging $641.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$51K
- Regeneron Healthcare Solutions, Inc.$50K
- Carl Zeiss Meditec, Inc.$31K
- Apellis Pharmaceuticals, Inc.$27K
- Genentech USA, Inc.$22K
- Astellas Pharma US Inc$16K
- plus $39K from 20 others
Across 1 payment — averaging $2892.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$3K
What the payments were for
- Consulting fees$92,64639%
- Speaking & faculty fees$110,87247%
- Travel & lodging$21,4889%
- Food & beverage$10,5714%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 76 | $50,706 |
| Regeneron Healthcare Solutions, Inc. | 89 | $50,264 |
| Carl Zeiss Meditec, Inc. | 35 | $31,156 |
| Apellis Pharmaceuticals, Inc. | 29 | $26,701 |
| Genentech USA, Inc. | 34 | $22,060 |
| Astellas Pharma US Inc | 22 | $16,016 |
| Bausch & Lomb Americas Inc. | 20 | $12,647 |
| Topcon Healthcare, Inc. | 4 | $4,664 |
| Thea Pharma Inc. | 3 | $3,190 |
| Tarsus Pharmaceuticals, Inc. | 11 | $3,158 |
| Regeneron | 3 | $2,990 |
| Novartis | 8 | $2,223 |
| Sun Pharmaceutical Industries Inc. | 5 | $2,038 |
| Glaukos Corporation | 1 | $1,500 |
| Heru, Inc. | 1 | $1,500 |
| Tearlab Corp | 2 | $1,356 |
| Harrow Eye, LLC | 3 | $1,070 |
| Aerie Pharmaceuticals, Inc. | 2 | $975 |
| LKC Technologies, Inc. | 1 | $450 |
| Carl Zeiss Meditec USA, Inc. | 1 | $350 |
| Sight Sciences, Inc. | 5 | $226 |
| Alcon | 2 | $105 |
| Oyster Point Pharma, Inc. | 5 | $103 |
| Mallinckrodt Hospital Products Inc. | 3 | $73 |
| Quidel Corporation | 1 | $33 |
| Eyevance Pharmaceuticals LLC | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA$51,960
- CIRRUS HD-OCT$27,587
- Syfovre$23,491
- Lucentis$21,529
- FORUM$19,946
- Humphrey HFA$18,665
- Izervay$15,806
- CLARUS$14,613
- LUMIGAN$11,626
- COMBIGAN$9,169
- CLARUS 500 Fundus Camera$8,353
- Glaucoma Workplace$5,350
- RESTASIS$4,855
- CIRRUS 5000 with AngioPlex$4,550
- Retina Workplace$4,550
- VUITY$4,080
- XIIDRA$3,863
- MIEBO$3,812
- CIRRUS 6000 with AngioPlex$3,500
- CLARUS 500$2,277
How this compares
$235,578 in reported general payments places this provider in the 95th percentile of 3,166 optometrist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 112 | $116,207 |
| Cyclosporine | 51 | $17,844 |
| CombiganBrimonidine Tartrate/Timolol | 18 | $5,608 |
| Alphagan PBrimonidine Tartrate | 22 | $4,246 |
| Loteprednol Etabonate | 36 | $3,348 |
| TobradexTobramycin/Dexamethasone | 12 | $3,166 |
| Latanoprost | 265 | $2,395 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 42 | $788 |
| Prednisolone Acetate | 31 | $774 |
| Brimonidine Tartrate | 23 | $376 |
| Dorzolamide Hcl | 19 | $329 |
| Timolol Maleate | 18 | $177 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 13 | $119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Alphagan P | $50,706 | $126,062152 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,166 optometrist providers in Florida.
Other optometrist in Miami
- Elise KramerMiami$168K
- Diana ShechtmanMiami$78K
- Angelica CifuentesMiami$68K
- Kristie DraskovicMiami$36K
- Arnaldo CarmouzeMiami$25K
- James HoffmanOrange Park$795K
- April JasperWest Palm Beach$553K
- Nora CothranLargo$505K
- Michael SluskyNorth Port$384K
- Katie SpearDefuniak Springs$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.